• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tirofiban in the treatment of cancer-associated ischemic stroke
CONCLUSIONS: Early administration of tirofiban in the treatment of mild to moderate ischemic stroke is safe, which can reduce 24-hour and 7-day NIHSS scores and has potential value.PMID:37140310 | DOI:10.26355/eurrev_202304_32142
Source: European Review for Medical and Pharmacological Sciences - May 4, 2023 Category: Drugs & Pharmacology Authors: Z-M Zhang Z-H Lin G-L Zhu Source Type: research

Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke?
Abstract Stroke and cerebrovascular disease are now the fifth most common cause of death behind other diseases such as heart, cancer and respiratory disease and accounts for approximately 40-50 fatalities per 100,000 people each year in the United States. Currently the only therapy for acute stroke, is intravenous administration of tissue plasminogen activator which was approved in 1996 by the FDA. Surprisingly no new treatments have come on the market since, although endovascular mechanical thrombectomy is showing promising results in trials. Recently focus has shifted towards a preventative therapy rather than t...
Source: Neuropharmacology - December 19, 2018 Category: Drugs & Pharmacology Authors: Lanigan SM, O'Connor JJ Tags: Neuropharmacology Source Type: research

Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment.
Authors: Lu X, Zhang Y, Wang L, Li G, Gao J, Wang Y Abstract The development of suitable drug delivery carriers is significant in biomedical applications to improve the therapeutic efficiency. Recent progress in nanotechnological fields, paved the way for the formulation of variety of drug carriers. The brain disorders such as ischemic stroke, brain cancer, and CNS disorders were poorly treated due to the presence of blood brain barrier that hinders the passage of drugs to the brain. Hence, the formulated drugs should have the ability to cross the blood-brain barrier (BBB) for ischemic stroke treatment. In the pres...
Source: Drug Delivery - February 17, 2021 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Cryptotanshinone possesses therapeutic effects on ischaemic stroke through regulating STAT5 in a rat model
CONCLUSION: Our findings not only enhance the understanding of the mechanisms underlying CT treatment, but also indicate its potential value as a promising agent in the treatment of ischaemic stroke. Further study will be valuable to examine the effects of CT on patients with ischaemic stroke.PMID:33915069 | DOI:10.1080/13880209.2021.1914672
Source: Pharmaceutical Biology - April 29, 2021 Category: Drugs & Pharmacology Authors: Feihong Zhu Hehe Chen Meifei Xu Xiajun Zhang Jing Yu Yali Pan Weixin Zhu Source Type: research

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Abstract The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of ther...
Source: Current Neuropharmacology - November 26, 2015 Category: Drugs & Pharmacology Authors: Gagalo I, Rusiecka I, Kocic I Tags: Curr Neuropharmacol Source Type: research

Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14